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Abstract
Background: Lisdexamfetamine dimesylate (LDX) is indicated for the treatment of attention-deficit/
hyperactivity disorder (ADHD) in children 6 to 12 years of age and in adults. In a previous laboratory
school study, LDX demonstrated efficacy 2 hours postdose with duration of efficacy through 12 hours.
The current study further characterizes the time course of effect of LDX.
Methods: Children aged 6 to 12 years with ADHD were enrolled in a laboratory school study. The
multicenter study consisted of open-label, dose-optimization of LDX (30, 50, 70 mg/d, 4 weeks) followed
by a randomized, placebo-controlled, 2-way crossover phase (1 week each). Efficacy measures included
the SKAMP (deportment [primary] and attention [secondary]) and PERMP (attempted/correct) scales
(secondary) measured at predose and at 1.5, 2.5, 5, 7.5, 10, 12, and 13 hours postdose. Safety measures
included treatment-emergent adverse events (AEs), physical examination, vital signs, and ECGs.
Results: A total of 117 subjects were randomized and 111 completed the study. Compared with placebo,
LDX demonstrated significantly greater efficacy at each postdose time point (1.5 hours to 13.0 hours), as
measured by SKAMP deportment and attention scales and PERMP (P  < .005). The most common
treatment-emergent AEs during dose optimization were decreased appetite (47%), insomnia (27%),
headache (17%), irritability (16%), upper abdominal pain (16%), and affect lability (10%), which were less
frequent in the crossover phase (6%, 4%, 5%, 1%, 2%, and 0% respectively).
Conclusion: In school-aged children (6 to 12 years) with ADHD, efficacy of LDX was maintained from
the first time point (1.5 hours) up to the last time point assessed (13.0 hours). LDX was generally well
tolerated, resulting in typical stimulant AEs.
Trial registration: Official Title: A Phase IIIb, Randomized, Double-Blind, Multi-Center, Placebo-
Controlled, Dose-Optimization, Cross-Over, Analog Classroom Study to Assess the Time of Onset of
Vyvanse (Lisdexamfetamine Dimesylate) in Pediatric Subjects Aged 6–12 With Attention-Deficit/
Hyperactivity Disorder.
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Background
Stimulants are the mainstay of pharmacotherapy for
attention-deficit/hyperactivity disorder (ADHD). Their
safety and efficacy have been well documented [1-3].
Within this class of medications, amphetamine and meth-
ylphenidate are the most widely prescribed agents for the
treatment of ADHD [4]. An early double-blind, parallel-
group study of dexamphetamine in 38 children with
hyperkinetic disorder demonstrated efficacy for dexam-
phetamine with 62% considered greatly improved overall
vs 17% for placebo [5]. Target symptoms such as hyperac-
tivity and distractibility were also significantly improved
by treatment. The adverse events associated with dexam-
phetamine in this study were those typically seen with
stimulants, including reduction in appetite, weight loss,
insomnia, stomach ache and changes in emotional
expression [5]. A second arm of the study with methylphe-
nidate found substantial similarity between the 2 medica-
tions in efficacy and safety. In the years since, immediate-
and sustained-release formulations of d-amphetamine
have been used extensively to treat ADHD with a number
of reports concluding that there is a high degree of simi-
larity in efficacy and tolerability between d-amphetamine
and methylphenidate and that differences are subtle and
often subject-specific ([1,6-8]. There is an important clin-
ical need for long-acting stimulant medications with effi-
cacy beyond 12 hours' duration among children with
ADHD who require symptom control that extends into
the later hours of the day [9].
Lisdexamfetamine dimesylate (LDX; Vyvanse®; Shire US
Inc) is a prodrug stimulant indicated for the treatment of
ADHD. LDX is a therapeutically inactive molecule that
subsequently upon ingestion is hydrolyzed by endog-
enous enzymes to l-lysine, a naturally occurring essential
amino acid, and active d-amphetamine, which is respon-
sible for its therapeutic effect [10]. Preliminary nonclini-
cal data suggest that conversion of LDX to d-
amphetamine and l-lysine may also occur in the blood
[11]. The conversion of LDX to d-amphetamine is
unlikely to be affected by gastrointestinal pH and varia-
tions in normal gastrointestinal transit times [12].
Clinical studies of LDX have been completed in school-
aged children (6–12 years) with ADHD. A 6-week, rand-
omized, double-blind, crossover study in a laboratory
school setting [13] similar to the current study showed
that LDX was significantly more effective in reducing
ADHD symptoms compared with placebo (P < .0001), as
measured by the Swanson, Kotkin, Agler, M-Flynn, and
Pelham deportment (SKAMP-D) subscale throughout the
day [14]. The SKAMP-D (see methods section for further
details on SKAMP and all subscales) was used to assess
behavioral manifestations of ADHD during analog class-
room sessions [14]. Efficacy in LDX-treated subjects com-
pared with placebo was significant beginning at 2 hours
postdose and lasted up to 12 hours postdose, the last time
point measured. LDX was generally well tolerated with
adverse events (AEs) similar to those seen with other
once-daily stimulants [13].
A second 4-week, multicenter, randomized, double-blind,
placebo-controlled, parallel-group trial in children with
ADHD evaluated the efficacy and safety of LDX (30, 50,
and 70 mg/d) over 4 weeks of treatment [10]. Significant
improvements in ADHD Rating Scale Version IV (ADHD-
RS-IV) [15] scores were noted for all doses of LDX com-
pared with placebo (all, P < .001) [10]. LDX produced sig-
nificant improvement in ADHD symptom control as early
as the first week of treatment, compared with placebo (P
< .001) [10]. Also parent ratings of their child's response
to treatment, measured by the ADHD Index on the Con-
ners' Parent Rating Scale (CPRS) [16], were improved and
maintained at each time point throughout the day (P <
.001 vs placebo and vs baseline at approximately 10 AM, 2
PM, and 6 PM). As in the previous study, LDX was generally
well tolerated, with an AE profile similar to that of other
extended-release stimulant products [10].
The present study replicated and expanded upon the find-
ings of the previous laboratory school study described
above, sharing methodologic similarities such as age of
subjects and use of a laboratory school protocol. Thus, the
onset of efficacy was investigated as early as 1.5 hours and
duration of efficacy was measured up to 13 hours follow-
ing dosing.
Study objectives
The primary objective of this study was to assess the initial
onset of efficacy of LDX compared with placebo, as meas-
ured by the SKAMP-D subscale (questions 5 through 8 on
the SKAMP scale), in children aged 6 to 12 years with
ADHD. The key secondary objective was to assess the
duration of efficacy of LDX compared with placebo, also
using the SKAMP-D subscale. Additional secondary
assessments of efficacy over time included the Permanent
Product Measure of Performance (PERMP), SKAMP atten-
tion (SKAMP-A) subscale (questions 1 through 4), the
SKAMP quality of work subscale (questions 9 through
11), the SKAMP total score, the ADHD-RS-IV, and Clinical
Global Impressions (CGI) scale. The study also evaluated
the safety of LDX through assessment of AEs, vital signs,
electrocardiograms (ECGs), and physical examination.
Materials and methods
This randomized, double-blind, multicenter, placebo-
controlled, dose-optimization, crossover, laboratory
school study of LDX was conducted at 7 study sites in the
United States. Subjects were recruited from June through
December 2007. All study activities were performed inChild and Adolescent Psychiatry and Mental Health 2009, 3:17 http://www.capmh.com/content/3/1/17
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accordance with the principles of the International Con-
ference on Harmonization Good Clinical Practice, 18th
World Medical Assembly (Helsinki 1964), and amend-
ments of the 29th (Tokyo 1975), the 35th (Venice 1983),
the 41st (Hong Kong 1989), and the 48th (South Africa
1996) World Medical Assemblies.
Study participants
This study enrolled boys and girls aged 6 to 12 years who
satisfied Diagnostic and Statistical Manual of Mental Disor-
ders, Fourth Edition, Text Revision (DSM-IV-TR) [17] criteria
for a primary diagnosis of ADHD, combined or hyperac-
tive-impulsive subtype. Subjects were also required to
have a baseline ADHD-RS-IV score ≥ 28, age-appropriate
intellectual functioning as determined by an intelligence
quotient (IQ) of ≥ 80 on the Kaufman Brief Intelligence
Test [18], the ability to complete the PERMP assessment,
and blood pressure within the 95th percentile for age,
gender, and height.
Key exclusion criteria were presence of a comorbid psychi-
atric condition with severe symptoms, conduct disorder,
or other medical condition that could confound assess-
ments, pose a risk to the subject, or prohibit study com-
pletion. Other exclusion criteria were adverse reaction or
nonresponsiveness to previous amphetamine therapy,
pregnancy, substance abuse, weight < 22.7 kg (50 lb),
body mass index > 98th percentile for age, seizure within
the last 2 years, tic or Tourette disorder, use of medication
with central nervous system effects (excluding bronchodi-
lators), or clinically significant laboratory and ECG abnor-
malities. Children whose current ADHD medication
provided effective control of symptoms with acceptable
tolerability were also excluded.
Study design
The study consisted of a screening phase (approximately 3
weeks), washout if applicable (up to 1 week, depending
on the subject's current medication), open-label, stepwise
dose optimization (4 weeks), double-blind, crossover
treatment with weekly assessments in a laboratory school
setting (2 weeks), and safety follow-up by telephone (30
days) (Figure 1). The use of some medications was pro-
hibited during the study due to their potential to interfere
with safety, efficacy, or tolerability assessments (norepine-
phrine reuptake inhibitors; investigational compounds;
antipsychotic, anxiolytic, or sedative-hypnotic medica-
tions; antidepressants; clonidine; antihypertensive agents;
psychostimulants; and sedating antihistamines). Except
for stimulant medications and sedating antihistamines
(which were discontinued up to 7 days before baseline),
use of these medications up to 30 days prior to screening
was also prohibited.
Subjects were required to visit the clinic at screening (visit
-1), baseline (visit 0), dose optimization (visits 1 through
4, corresponding to weeks 1 through 4), and double-blind
treatment (visits 5 and 6, which were analog classroom
sessions in the laboratory school setting). Visit 6 also
served as the end-of-study visit.
Administration of study drug
Following screening and washout, eligible subjects
entered the open-label dose-optimization phase, during
which they began receiving LDX followed by evaluation
for efficacy and tolerability of that dosage approximately
7 days later. Dosage was initiated at 30 mg/d LDX and
adjusted to the next available dose at weekly intervals,
until optimal dose was reached. Optimal dose was
defined as the dose that produced a reduction in ADHD-
Study design Figure 1
Study design. V: visit; LDX: lisdexamfetamine dimesylate.
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RS-IV score ≥ 30% and CGI-Improvement (CGI-I) score of
1 or 2 and had tolerable side effects. Tolerability was
determined by the investigator, based on review of AEs
and clinical judgment. Once reached, the optimal dose
was maintained for the remainder of the dose-optimiza-
tion phase and was used for the double-blind treatment
sequence period. Clinicians could increase the current
dose to provide additional symptom control. One dose
reduction was permitted if subjects experienced unaccept-
able tolerability of the current dose. Subjects were discon-
tinued if they were unable to tolerate LDX or had not
reached their optimal dose by visit 4. The dose dispensed
at visit 3 was the dose used during the double-blind treat-
ment sequence period. During visit 4, subjects attended a
half-day practice laboratory school with analog classroom
sessions to become familiar with classroom schedules and
procedures. SKAMP assessments were performed, and 3 to
5 practice PERMP tests were given during the practice ses-
sion.
Following dose optimization, subjects entered the 2-week
double-blind treatment period. Subjects were randomized
to receive daily LDX treatment (at the optimized dose) for
1 week followed by daily placebo capsules (identical in
appearance to LDX capsules) for 1 week, or vice versa. For
the first 6 days of each week during double-blind treat-
ment, study drug was administered by the parent. On the
last day of each week, with subject having taken LDX or
placebo for the preceding 6 days according to their rand-
omization schedule, the daily dose was administered by
study staff in the laboratory school at the start of the ana-
log classroom assessment day.
Ideally, each session had a cohort of 10 to 16 participants;
however, classroom size could be increased to 18 subjects
with prior approval from the sponsor. Cohort size ranged
from 6 subjects to 17 subjects with most between 11 and
15 subjects. Two of the 7 study sites enrolled 1 cohort each
with fewer than 10 subjects (6 and 8, respectively); 3 of
the 7 sites enrolled 1 cohort each of 13 to 17 subjects; and
2 of the 7 sites enrolled 2 cohorts each of 11 to 17 subjects
each. At visits 5 and 6 (laboratory school days), the sub-
jects arrived at 6 AM, and assessments of SKAMP and
PERMP were taken at 0.5 hours predose (6:30 AM). Sub-
jects then received their randomized treatment (7 AM).
SKAMP and PERMP assessments were performed during
analog classroom sessions as noted below. SKAMP assess-
ments were performed by observers who were provided
with training to help ensure reliability. The laboratory
school day ended at approximately 8:30 PM.
A follow-up telephone call was made approximately 30
days after the subject's last dose of study drug to collect
information on any ongoing or new AEs, serious AEs, and
concomitant medications. Appropriate follow-up was
continued until the investigator judged that all safety con-
cerns were resolved.
Outcome measures
Efficacy
Primary efficacy measure
The primary efficacy measure was the SKAMP-D subscale.
The SKAMP scale is a validated rating scale that assesses
manifestations of ADHD in a classroom setting through
several subscales, including deportment (behavior) and
attention [14]. SKAMP assessments were conducted dur-
ing a half-day practice of the laboratory school visit (visit
4). During the full-day visits (visits 5 and 6), SKAMP
assessment times were 0.5 hours predose and at 1.5, 2.5,
5, 7.5, 10, 12, and 13 hours postdose. Multiple SKAMP
assessments were completed at the end of individual class-
room sessions across the day by observers who rated each
subject on 13 items, using a 7-point impairment scale (0
= normal, 6 = maximal impairment). In this study,
SKAMP-D comprised 4 of the 13 items on the SKAMP
scale: interacting with other children, interacting with
adults, remaining quiet according to classroom rules, and
staying seated according to classroom rules [14,19].
SKAMP-D scores were calculated as the mean of the rat-
ings for these 4 items at each time point of each visit.
Mean SKAMP-D scores at visits 5 and 6 were also calcu-
lated as the mean of the ratings for these 4 items over all
postdose time points of each visit.
Secondary efficacy measures
The PERMP, a 5-page math test consisting of 80 problems
per page (total of 400 problems) [19], was used in this
study to evaluate effortful performance in the classroom
as a measure of efficacy. Subjects were instructed to work
at their seats and to complete as many problems as possi-
ble in 10 minutes. The appropriate level of difficulty for
each student was determined previously based on results
of a math pretest administered at screening. Performance
was evaluated using two scores: PERMP-A (number of
problems attempted) and PERMP-C (number of prob-
lems correct). The PERMP was completed during analog
classroom sessions at the same time points as the SKAMP
scale. To avoid taking the same test more than once during
the study, subjects received randomized problems in a dif-
ferent version of the test at each assessment.
The SKAMP-A subscale is a measure of attention and com-
prises the following 4 items on the SKAMP scale: getting
started on assignments, sticking with tasks, attending to
an activity, and making activity transitions [14,19]. The
SKAMP quality of work subscale comprises 3 items: com-
pleting assigned work, performing work accurately, and
being careful and neat while writing or drawing. The
scores for SKAMP-A, SKAMP quality of work, and SKAMPChild and Adolescent Psychiatry and Mental Health 2009, 3:17 http://www.capmh.com/content/3/1/17
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total were calculated as the mean of the ratings for the
items making up the score at each time point of each visit.
The ADHD-RS-IV [15] is a clinician-rated scale that
reflects current symptoms of ADHD based on DSM-IV-TR
criteria; it is a global assessment that measures the severity
of symptoms from visit to visit, but is not being utilized to
assess symptoms of ADHD over the course of the day. The
ADHD-RS-IV consists of 18 items that are grouped into 2
subscales (hyperactivity/impulsivity and inattention).
Each item is scored on a 4-point scale from 0 (no symp-
toms) to 3 (severe symptoms), yielding a total score of 0
to 54. The ADHD-RS-IV was administered at baseline and
each visit thereafter to assess efficacy.
The CGI [20] provides a global evaluation of baseline
severity and improvement over time, and, similarly as the
ADHD-RS-IV scale does, measures global impressions of
severity from visit to visit but not over the course of the
day. At baseline, the investigator used the CGI-Severity
(CGI-S) to rate severity on a scale that ranged from 1 (nor-
mal, not at all ill) to 7 (among the most extremely ill sub-
jects) plus a not assessed option. At each visit thereafter,
the clinician used the CGI-I to rate improvement relative
to baseline on a scale ranging from 1 (very much
improved) to 7 (very much worse) plus a not assessed
option. For analysis, CGI-I scores were dichotomized so
that very much improved (CGI-I score of 1) and much
improved (CGI-I score of 2) were combined into 1 cate-
gory (improved), and the remaining responses were com-
bined into the other category (not improved). CGI-I
scores of 0 (not assessed) were not included in the analy-
sis.
Safety
AEs, concomitant medications, and vital signs (including
systolic blood pressure [SBP], diastolic blood pressure
[DBP], and pulse) were recorded at each visit. ECGs were
conducted at screening (visit -1), baseline (visit 0), and
the end-of-study visit (visit 6). A physical examination
was conducted at screening and the end-of-study visit.
Clinical laboratory tests (including hematology, chemis-
try, and urinalysis) were conducted only at screening.
Treatment-emergent AEs (TEAEs), referring to events with
onset after the first date of treatment, and no later than 3
days following termination of treatment, were recorded
separately for the dose-optimization phase and the dou-
ble-blind laboratory school phase of the study.
Statistical analyses
Determination of sample size for the primary comparison
of time of onset of LDX versus placebo was based on anal-
ysis of SKAMP-D scores from a previous crossover study
[13] as well as other analog classroom design studies in
ADHD. Assuming a standard deviation (SD) of 0.95 (the
maximum SD reported in the previous LDX crossover
study) and based on an average difference in SKAMP-D
scores between placebo and LDX of 0.50 units for hours 1
and 2 in the previous study, 96 subjects (48 subjects in
each treatment sequence) would need to complete the
study to detect a true difference of 0.50 units in mean
SKAMP-D scores between placebo and LDX at 95% power
when testing at a significance level of α = .05 (2-sided).
However, 128 subjects were planned for enrollment, since
as many as 25% of subjects were predicted to discontinue
based on the proportion of subjects discontinuing prema-
turely in prior LDX studies. All statistical tests were 2-sided
and performed at the 0.05 significance level.
Efficacy
The primary population for efficacy assessments was the
intent-to-treat population (ITT) population, which con-
sisted of all randomized subjects who received at least 1
dose of study medication with at least 1 postrandomiza-
tion measurement of the primary efficacy variable (mean
SKAMP-D score over the course of a day) available for
analysis.
The primary efficacy measure was SKAMP-D subscale
score at each time point and mean score throughout the
day. The primary objective was to assess time of onset of
LDX compared with placebo as measured by SKAMP-D,
with a key secondary objective to assess duration of effi-
cacy of LDX using this subscale. A linear mixed model was
used to analyze the mean SKAMP-D score as well as the
SKAMP-D scores for each time point. In this model, the
fixed effects were sequence, period, and treatment, while
the random effect was subject-within-sequence. Raw
means, least-squares (LS) means, differences in LS means,
and 95% confidence interval (CI) for the difference
between treatment groups, P values, and model results
were calculated for each postdose time point and for
mean score over the treatment day for the ITT population.
A post hoc analysis examined change from predose for
SKAMP-D, PERMP-A, PERMP-C, and SKAMP-A. Other
post hoc analyses also examined SKAMP-D scores by opti-
mized dose and by study site. Postdose SKAMP-D scores
were analyzed by t-test on the change from predose within
group. Potential site and treatment interactions were
examined using the primary model with investigative-site
and site-by-treatment interactions added as factors at the
significance level of 0.10.
Since the study had a crossover design and assessed dura-
tion of efficacy, the last observation carried forward
(LOCF) method was not a valid approach for data that
were incomplete because of discontinuation or unavaila-
bility. Therefore, incomplete data due to these reasons
were set as missing for purposes of statistical analysis.Child and Adolescent Psychiatry and Mental Health 2009, 3:17 http://www.capmh.com/content/3/1/17
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Safety
Safety data for the dose-titration period were analyzed
using combined data from all subjects in the safety popu-
lation (defined as those subjects who entered the dose-
titration period and received open-label treatment). Safety
data from the double-blind sequence period were ana-
lyzed using data from each treatment group where appli-
cable in the randomized population (defined as all
randomized subjects who received at least 1 dose of study
medication during the double-blind crossover period).
Safety summaries for vital signs were presented by visit for
each treatment group in the safety population. Safety
summaries for ECGs were presented for the baseline and
end-of-study visits, for all subjects in the safety population
combined. For each AE, frequency was calculated by treat-
ment group and for number and percentage of subjects
who reported the event. Continuous variables related to
these safety assessments were summarized using the
number of observations, mean, SD, minimum, median,
and maximum values, while categorical (nominal) varia-
bles were summarized using number of observations and
percentages.
Results
Subjects
A total of 129 subjects were enrolled and entered the
open-label, dose-optimization phase (Table 1). Of these,
117 (90.7%) were randomized to the double-blind cross-
over phase, 113 (87.6%) were included in the ITT popula-
tion, and 111 (86.0%) completed the study. Four of the
117 subjects in the randomized population were not
included in the ITT population because they did not have
at least 1 SKAMP-D score available after randomization.
Mean (SD) age of the safety population was 10.1 (1.5)
years, and mean (SD) weight was 72.8 (17.3) lb. The
safety population was made up of 76.0% (n = 98) male
subjects and 70.5% (n = 91) Caucasians. At baseline, all
subjects were diagnosed with the combined ADHD sub-
type and had a mean (SD) ADHD-RS-IV total score of 42.4
(7.1). According to the prespecified statistical analysis
plan, efficacy analyses were based on the ITT population
of 113 subjects and safety analyses were based on the
safety population of 129 subjects.
Of the 7 study sites, 1 site was also a site from the previous
LDX analog classroom study. Per the principal investiga-
tor of that site, there was no subject overlap and, there-
fore, no subjects with prior exposure to LDX from clinical
trials were included in this study [Previous exposure clar-
ification. Personal Communication with AC. Childress on
December 8, 2008].
Twelve of the 18 study discontinuations (Table 1)
occurred during dose optimization while each subject was
receiving 30 mg/d LDX (8 due to AEs, 1 due to protocol
violation, and 3 due to withdrawal of consent). Six dis-
continuations occurred during the crossover phase: 2
while the subject was receiving LDX (protocol violation,
withdrawal of consent), and 4 while the subjects were
receiving placebo (loss to follow-up in 2 subjects, AE in 1
subject, and withdrawal of consent in 1 subject). No sub-
ject discontinued due to lack of efficacy of active treat-
ment.
Efficacy assessments
Primary measure
SKAMP-D
LDX demonstrated significant improvement on the
SKAMP-D compared with placebo, at 1.5 hours (the first
postdose time point measured; primary endpoint) and
continuing through all time points up to and including
13.0 hours postdose (the last time point measured; key
secondary endpoint). There was significant separation of
LDX from placebo at all postdose time points for the
SKAMP-D score analysis (as measured by LS mean [SE]; P
< .005 for all time points) (Table 2) and [(Figure 2) top].
Analysis of change from predose [(Figure 2) bottom] was
performed using the same statistical model that was used
for analysis of the primary efficacy variable, SKAMP-D
score, and was designed, together with the summary sta-
tistics for actual scores by time point to provide additional
context. Post hoc analysis of SKAMP-D scores in the LDX
group showed that significant improvement relative to
predose was seen at all postdose time points except 12 and
13 hours. At 12 and 13 hours postdose, SKAMP-D scores
in this group were numerically worse but not statistically
different from predose levels. Conversely, SKAMP-D
scores were significantly worse than predose at all post-
dose time points in the placebo group. Negative scores
indicated improvement when reporting SKAMP changes.
The differences in LS means (95% CI) of LDX vs placebo
at 1.5 hours and 13.0 hours were -0.45 (-0.62, -0.28; P <
.0001) and -0.26 (-0.43, -0.08; P < .005), respectively. The
mean score difference in LS means (95% CI) of LDX vs
placebo was -0.74 (-0.85, -0.63; P < .0001).
Secondary measures
PERMP-A and PERMP-C
Results for PERMP-A and PERMP-C were also consistent
with results from the SKAMP-D. For PERMP-A and
PERMP-C, efficacy was shown at each postdose time
point, at 1.5 hours and continuing up to and including
13.0 hours (Figures 3). LDX showed separation from pla-
cebo at all postdose time points for both the PERMP-A
[(Figure 3), actual and change from predose, top and bot-
tom, respectively] and PERMP-C [(Figure 3), actual and
change from predose, top and bottom, respectively] score
analyses (as measured by LS mean [SE]; P < .0001 for all
time points). LS mean (SE) PERMP-A and PERMP-C
scores for LDX groups [85.54 (4.88) and 81.86 (4.84),Child and Adolescent Psychiatry and Mental Health 2009, 3:17 http://www.capmh.com/content/3/1/17
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respectively] were significantly different from placebo
groups [102.43 (4.88) and 99.17 (4.84), respectively; P <
.005] at predose assessments (Figures 3). The differences
in LS means (95% CI) of LDX vs placebo in PERMP-A at
1.5 hours and 13.0 hours were 16.97 (9.39, 24.56) and
28.28 (21.51, 35.04), respectively (both, P < .0001). The
differences in LS means (95% CI) of LDX vs placebo in
PERMP-C at 1.5 hours and 13 hours were 19.10 (12.25,
25.94) and 28.14 (21.46, 34.83), respectively (both, P <
.0001).
SKAMP-A, SKAMP Quality of Work, and SKAMP Total Scores
Results from SKAMP-A were consistent with results from
the primary efficacy measure (SKAMP-D). For SKAMP-A,
LDX demonstrated significant efficacy compared with pla-
cebo at 1.5 hours (the first postdose time point measured)
and continuing through all time points up to and includ-
ing 13.0 hours postdose (the last time point measured).
LDX showed complete separation from placebo at all
postdose time points for the SKAMP-A score analysis (as
measured by LS mean (SE) and LS mean change (SE) from
predose; P ≤ .001 vs placebo for all time points; Table 2
and [(Figure 2), top and bottom], respectively). Predose
Table 1: Subject Demographics (Safety Population) and Disposition
Subject Category LDX Optimal Dose
30 mg/d 50 mg/d 70 mg/d All Doses
Safety population 58 (100.0) 50 (100.0) 21 (100.0) 129 (100.0)
Age (years) Mean (SD) 9.8 (1.5) 10.2 (1.3) 10.4 (1.9) 10.1 (1.5)
Gender
Male n (%) 44 (75.9) 37 (74.0) 17 (81.0) 98 (76.0)
Female 14 (24.1) 13 (26.0) 4 (19.0) 31 (24.0)
Race
Caucasian 38 (65.5) 37 (74.0) 16 (76.2) 91 (70.5)
Black or African American 11 (19.0) 4 (8.0) 2 (9.5) 17 (13.2)
Native Hawaiian or Other Pacific Islander n (%) 0 1 (2.0) 0 1 (0.8)
Asian 0 0 0 0
American Indian or Alaska Native 2 (3.4) 0 0 2 (1.6)
Other 7 (12.1) 8 (16.0) 3 (14.3) 18 (14.0)
Ethnicity
Hispanic or Latino n (%) 9 (15.5) 11 (22.0) 6 (28.6) 26 (20.2)
Not Hispanic or Latino 49 (84.5) 39 (78.0) 15 (71.4) 103 (79.8)
ADHD-RS-IV Total Score at Baseline Mean (SD) 40.5 (6.7) 43.4 (7.5) 45.7 (5.7) 42.4 (7.1)
Randomized population 46 (79.3) 50 (100.0) 21 (100.0) 117 (90.7)
Intent-to-treat population 46 (79.3) 47 (94.0) 20 (95.2) 113 (87.6)
Completed study 44 (75.9) 47 (94.0) 20 (95.2) 111 (86.0)
Reason for discontinuation*
Adverse event† 8 (13.8) 1 (2.0) 0 9 (7.0)
Protocol violation 1 (1.7) 1 (2.0) 0 2 (1.6)
Consent withdrawn 3 (5.2) 1 (2.0) 1 (4.8) 5 (3.9)
Lost to follow-up 2 (3.4) 0 0 2 (1.6)
Lack of efficacy 0 0 0 0
Other 0 0 0 0
LDX: lisdexamfetamine dimesylate; ADHD-RS-IV: Attention-Deficit/Hyperactivity Disorder Rating Scale IV
*Includes all subjects who discontinued during dose-optimization and crossover periods based on optimized dose.
†All AEs leading to discontinuation occurred during dose optimization. Eight discontinuations occurred before randomization. These subjects were 
taking 30 mg/d LDX when the discontinuation-related AE occurred. One discontinuation occurred after randomization. This subject was taking 50 
mg/d LDX when he experienced acute gastritis, causing him to miss the visit 4 practice day.Child and Adolescent Psychiatry and Mental Health 2009, 3:17 http://www.capmh.com/content/3/1/17
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SKAMP-A scores were significantly different between the
LDX group and placebo group (Table 2 and Figure 2). The
differences in LS means (95% CI) of LDX vs placebo in
SKAMP-A at 1.5 hours and 13 hours were -0.43 (-0.62, -
0.23) and -0.47 (-0.62, -0.31), respectively (both, P  <
.0001).
Results of both SKAMP quality of work and SKAMP total
scores (Table 2) were consistent with those seen with
SKAMP-D. SKAMP quality of work subscale LS mean (SE)
scores showed significant efficacy of LDX starting at the
2.5-hour time point (1.53 [0.09] LDX vs 2.42 [0.09] pla-
cebo;P < .0001). Significant efficacy compared with pla-
cebo continued at each postdose time point thereafter, up
to and including 13.0 hours (all, P < .005). SKAMP total
scores also showed significant efficacy compared with pla-
cebo at all points beginning at 1.5 hours and up to and
including 13.0 hours (P < .0001). Predose SKAMP quality
of work and total scores in the LDX groups were signifi-
cantly different from those in the placebo groups (Table
2). The demonstration of efficacy at each postdose time
point for SKAMP total scores was consistent with that seen
for SKAMP-D and SKAMP-A.
Dose analysis
Overall mean difference (95% CI) for placebo vs LDX was
analyzed by optimized dose groups for SKAMP-D,
SKAMP-A, SKAMP quality of work, and SKAMP total
scores (Table 3), and these scores across optimized dose
groups during the open-label, nonrandomized phase of
this study were found to be consistent.
Site analysis
The differences in LS mean (95% CI) for SKAMP-D scores
for placebo vs LDX treatment by investigative site were all
in the direction of improvement with LDX compared to
placebo. Differences in LS mean (95% CI) scores between
placebo and LDX ranged from -0.47 (-0.70 to -0.24) to -
1.04 (-1.35 to -0.72). Variability between investigative
sites in mean predose SKAMP-D scores was apparent but
this did not seem to unduly influence postdose scores.
Statistical interaction model analysis with investigative
site and site by treatment added as factors found no signif-
icant interaction at the 0.10 level (P = .153).
ADHD-RS-IV
During the 4 weeks of the open-label, dose-optimization
phase (visit 1 through visit 4), ADHD-RS-IV total scores
and subscale scores decreased (improved) from baseline
for each LDX dose strength. For the 2 weeks of the crosso-
ver period (visit 5 and visit 6), significant reductions in
ADHD-RS-IV total and subscale scores from baseline were
observed with LDX compared with placebo (by difference
in LS means; P < .0001). LS mean (SE) change scores for
LDX were -25.8 (1.20), -12.5 (0.62), and -13.3 (0.64) for
ADHD-RS-IV total, inattention, and hyperactivity/impul-
sivity scores, respectively. LS mean change (SE) scores for
placebo were -8.7 (1.20), -4.1 (0.62), and -4.5 (0.64) for
ADHD-RS-IV total, inattention, and hyperactivity/impul-
sivity scores, respectively.
CGI-I scores
At the end of the open-label, dose-optimization phase
(visit 4), all subjects (100%) were rated as improved (ie,
either very much improved [CGI-I of 1; 64.6%] or much
improved [CGI-I of 2; 35.4%]). For the crossover period,
93 (82.3%) subjects were improved on LDX (58.4% very
much improved and 23.9% much improved) vs 22
(19.5%) on placebo. Of those subjects, 81 (71.7%) were
improved while receiving LDX but not placebo, while 10
subjects (8.8%) were improved on placebo but not on
LDX. The overall difference between LDX and placebo
treatment was statistically significant (P < .0001).
Safety assessment
No deaths or serious AEs were reported during this study.
The most common TEAEs with an incidence ≥ 10% during
the dose-optimization phase are reported in Table 4. Most
Table 2: LS Mean (SE) SKAMP Scores at Predose and 1.5 and 13.0 Hours Postdose*
SKAMP-D
LS Mean (SE)
SKAMP-A
LS Mean (SE)
SKAMP-Quality of 
Work
LS Mean (SE)
SKAMP-Total
LS Mean (SE)
LDX Placebo LDX Placebo LDX Placebo LDX Placebo
Predose 0.88 (0.09) 0.71 (0.09) 1.50 (0.10)† 1.21 (0.10) 2.90 (0.08)† 1.72 (0.08) 1.68 (0.07)† 1.22 (0.07)
1.5 hours 0.70 (0.09)† 1.14 (0.09) 1.03 (0.10)† 1.45 (0.10) 1.75 (0.09) 1.95 (0.09) 1.15 (0.08)† 1.62 (0.08)
13 hours 1.05 (0.10)† 1.31 (0.10) 1.14 (0.10)† 1.61 (0.10) 2.13 (0.10)† 2.46 (0.10) 1.43 (0.08)† 1.85 (0.08)
LS: least squares; LDX: lisdexamfetamine dimesylate; SKAMP: Swanson, Kotkin, Agler, M-Flynn, and Pelham scale; D: deportment; A: attention
*Lower SKAMP total and subscale scores are indicative of improvement.
†P < .005 vs placebo.Child and Adolescent Psychiatry and Mental Health 2009, 3:17 http://www.capmh.com/content/3/1/17
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Time course of SKAMP-D (closed symbols) and SKAMP-A (open symbols) assessment over the laboratory school day Figure 2
Time course of SKAMP-D (closed symbols) and SKAMP-A (open symbols) assessment over the laboratory 
school day. LS mean (SE) actual scores (top) and change from predose (bottom) for LDX (squares) and placebo (circles) at 
predose (-0.5 h) and at 1.5, 2.5, 5, 7.5, 10, 12, and 13 h postdose. Scores were compared using a linear mixed model with 
sequence, period, and treatment as fixed effects and subject within sequence as a random effect. Lower scores denote 
improvement. *Denotes P < .005 LDX compared with placebo for SKAMP-D. †Denotes P ≤ .001 LDX compared with placebo 
for SKAMP-A.
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LDX: lisdexamfetamine dimesylateChild and Adolescent Psychiatry and Mental Health 2009, 3:17 http://www.capmh.com/content/3/1/17
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Time course of PERMP-A (closed symbols) and PERMP-C (open symbols) assessment over the laboratory school day Figure 3
Time course of PERMP-A (closed symbols) and PERMP-C (open symbols) assessment over the laboratory 
school day. LS mean (SE) actual scores (top) and change from predose (bottom) for LDX (squares) and placebo (circles) at 
predose (-0.5 h) and at 1.5, 2.5, 5, 7.5, 10, 12, and 13 h postdose. Scores were compared using a linear mixed model with 
sequence, period, and treatment as fixed effects and subject within sequence as a random effect. Higher scores denote 
improvement. *Denotes P < .0001 LDX compared with placebo for PERMP-A. †Denotes P < .0001 LDX compared with pla-
cebo for PERMP-C.
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subjects reported mild or moderate TEAEs during this
phase; 5 subjects (3.9%) reported severe TEAEs (blunted
affect, insomnia, increased insomnia, and irritability each
reported in 1 subject; accidental overdose and upper
abdominal pain both reported in the same subject). The
investigator deemed that the TEAEs were related to study
drug in 100 subjects (77.5%).
During the double-blind crossover period, the investiga-
tor deemed that the TEAEs were related to study drug in 20
subjects (17.4%) in the LDX group and 8 subjects (7.0%)
in the placebo group. There were no new TEAEs with an
incidence  ≥ 10% during the double-blind crossover
period. TEAEs reported during this phase were mild or
moderate, with the exception of severe insomnia in 1
LDX-treated subject.
All TEAEs leading to discontinuation occurred prior to
participation in the double-blind crossover phase (see
Table 1 for a summary of subject disposition). Most TEAEs
resulting in discontinuations during the dose-optimiza-
tion phase were judged to be related to study drug and
most were moderate in severity and resolved after discon-
tinuation. TEAEs that led to discontinuations are depicted
in Table 5. These TEAEs were judged to be related to treat-
ment and resolved after discontinuation. No TEAEs dur-
ing the crossover phase resulted in discontinuations.
Suicidal ideation, related to study drug after 4 days expo-
Table 3: Mean Difference in LS Means (95% CI) for SKAMP Scales by Optimized Dose Group*
LDX Dose Group SKAMP-D SKAMP-A Quality of Work Total
30 mg/d (n = 46) -0.70 -0.59 -0.60 -0.73
(-0.88, -0.52) (-0.79, -0.40) (-0.78, -0.42) (-0.87, -0.59)
50 mg/d (n = 47) -0.68 -0.61 -0.67 -0.74
(-0.84, -0.52) (-0.78, -0.45) (-0.81, -0.54) (-0.86, -0.62)
70 mg/d (n = 20) -0.96 -0.89 -0.68 -0.99
(-1.30, -0.63) (-1.15, -0.64) (-0.94, -0.42) (-1.24, -0.74)
LDX: lisdexamfetamine dimesylate; LS: least squares; SKAMP: Swanson, Kotkin, Agler, M-Flynn, and Pelham scale; D: deportment; A: attention; CI: 
confidence interval
*Negative scores indicate improvement relative to placebo.
Table 4: TEAEs ≥ 10% During Dose-Optimization and Crossover Phases
Adverse Event
Preferred Term
Dose-Optimization Phase (Safety Population) Crossover Phase
(Randomized Population)
LDX All Doses
(N = 129)
n (%)
LDX All Doses
(n = 115)
n (%)
Placebo
(n = 115)
n (%)
Any adverse event 110 (85.3) 38 (33.0) 22 (19.1)
Affect lability 13 (10.1) 0 (0.0) 1 (0.9)
Decreased appetite 61 (47.3) 7 (6.1) 1 (0.9)
Headache 22 (17.1) 6 (5.2) 2 (1.7)
Insomnia 35 (27.1) 5 (4.3) 0 (0.0)
Irritability 21 (16.3) 1 (0.9) 1 (0.9)
Upper abdominal pain 20 (15.5) 2 (1.7) 3 (2.6)
TEAEs were assigned to either the open-label dose-optimization phase or the double-blind crossover phase of the study and were summarized 
separately. TEAEs that continued uninterrupted from the dose-optimization to the crossover phase without a change in severity were counted only 
in the dose-optimization phase category. TEAEs with a change in severity across phases or that resolved and then restarted in the crossover phase 
were counted both in the dose-optimization and crossover arms. TEAEs for which a missing or incomplete start date made it impossible to 
determine in which phase of the study they started were counted as starting in the dose-optimization phase.
LDX: lisdexamfetamine dimesylate; TEAEs: treatment-emergent adverse eventsChild and Adolescent Psychiatry and Mental Health 2009, 3:17 http://www.capmh.com/content/3/1/17
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sure to LDX during dose optimization and assessed as
mild in severity, occurred in 1 subject, an 11-year-old
male subject with no other reported clinical conditions at
baseline. This subject's suicidal ideation resolved with dis-
continuation of LDX with no additional reported AEs at
follow-up 1 month after discontinuation.
At baseline (n = 129), mean (SD) SBP, DBP, and pulse rate
were 100.3 (9.1) mm Hg, 61.2 (7.4) mm Hg, and 84.0
(11.1) bpm, respectively. At the end of the dose-optimiza-
tion phase (week 4; n = 117), the mean (SD) change in
vital signs for all LDX doses combined was -0.3 (10.3)
mm Hg SBP, 2.1 (8.0) mm Hg DBP, and -4.3 (12.4) bpm
pulse rate. There were no dose-related changes in vital
signs in the dose-optimization phase. During the crosso-
ver period, vital signs increased slightly from baseline for
both the LDX- and placebo-treated subjects. Maximum
mean (SD) increases from baseline in blood pressure were
4.2 (9.2) mm Hg for SBP (70 mg LDX group at 8 hours
postdose), and 4.7 (8.5) mm Hg for DBP (70 mg LDX
group at 8 hours postdose). The maximum mean (SD)
increase in pulse was 9.9 (9.8) bpm (70 mg LDX group at
12.5 hours postdose) compared with 6.6 (12.9) bpm for
the placebo group and 6.6 (13.6) bpm for all active doses
of LDX combined at the same time point. Also, mean
(SD) increase in pulse at 8.0 hours postdose was 3.5
(13.7) bpm for the 70 mg LDX group, similar to 4.1 (12.8)
bpm for the placebo group and 2.6 (13.0) bpm for all
active LDX doses combined at the same time point. Con-
sistent with prior clinical studies of LDX, ECG interval
data exhibited no clinically meaningful trends. Heart rate
increased slightly from baseline consistent with pulse rate
findings. At study baseline, mean (SD) QTcF (Fridericia)
interval was 389.0 (17.3) msec in subjects receiving pla-
cebo (n = 58) and 392.0 (15.4) msec in subjects receiving
LDX (n = 67; all doses). At study end or early termination,
mean (SD) QTcF was 389.8 (14.3) msec in subjects receiv-
ing placebo (n = 58) and 397.3 (19.5) msec in subjects
receiving LDX (n = 66; all doses). At study end, 14 subjects
had ≥ 1 abnormal result or abnormal change from base-
line in QT, QTcF, or QTcB-Bazett reading after study base-
line. However, no subject had a QT, QTcF, or QTcB
interval ≥ 480 msec or a change from baseline > 60 msec.
Small decreases in weight from baseline were observed
and were consistent with the known effect of psychostim-
ulants [21-23]. Baseline mean weight (SD) in evaluable
subjects (n = 128) at visit 1 was 75.1 (18.1) lb. Mean (SD)
change from baseline in body weight was -2.5 (6.9) lb (n
= 117) at the end of the dose optimization phase and was
-2.6 (6.4) lb in evaluable subjects (n = 115) at study end.
Discussion
This study demonstrated an onset of action for LDX at 1.5
hours (the first postdose time point measured), with dura-
tion of efficacy up to 13 hours postdose as assessed during
the crossover treatment period. The symptoms of ADHD
may extend beyond the school day and continue into
afterschool activities and family interactions. This trial is
the first to demonstrate duration of efficacy up to 13
hours postdose compared with placebo for an approved
oral ADHD stimulant medication and may provide an
Table 5: TEAEs Leading to Discontinuation by System Organ 
Class and Preferred Term (All Occurrences: Safety Population, 
N = 129)
System Organ Class Preferred Term n (%)
Gastrointestinal 4 (3.1)
Abdominal pain 2 (1.6)
Diarrhea 1 (0.8)
Nausea 2 (1.6)
Vomiting 2 (1.6)
General 4 (3.1)
Fatigue 2 (1.6)
Irritability 2 (1.6)
Investigations 1 (0.8)
Weight decrease 1 (0.8)
Metabolic/nutritional 3 (2.3)
Anorexia 2 (1.6)
Decreased appetite 1 (0.8)
Nervous system 2 (1.6)
Amnesia 1 (0.8)
Psychomotor hyperactivity 2 (1.6)
Tardive dyskinesia
(lip-smacking)
1 (0.8)
Psychiatric 5 (3.9)
Insomnia/sleep disorder 4 (3.1)
Suicidal ideation 1 (0.8)
Tearfulness 1 (0.8)
TEAEs: treatment-emergent adverse eventsChild and Adolescent Psychiatry and Mental Health 2009, 3:17 http://www.capmh.com/content/3/1/17
Page 13 of 15
(page number not for citation purposes)
important treatment option for prolonged ADHD symp-
tom control.
Although pharmacokinetic (PK) data were not collected
in this study, data from other studies of adults [24] and
children [13] may assist in describing this extended dura-
tion of action [25]. In both studies, PK data at the 70 mg
dose were reported. In healthy adult volunteers, the
plasma concentrations showed intact LDX levels reaching
their maximum concentration at 1.1 hours after ingestion
and then declined to 0 by 5 hours postdose. However,
mean plasma levels of d-amphetamine reached their max-
imum at 3.7 hours and did not approach 0 until 72 hours
following the final dose. In fact, the active d-ampheta-
mine was about 18 times that of the intact LDX when drug
absorption was compared [24]. In children, the PK data
were collected only up to 12 hours postdose. Since the
plasma level of d-amphetamine after administration of
LDX 70 mg was 86.7 ng/mL at 12 hours [26], it is reason-
able to infer that the d-amphetamine levels would con-
tinue to be apparent even beyond the 13-hour time
period. Thus, the earlier onset and longer duration of effi-
cacy or therapeutic activity summarized for the present
study seem to follow the known PK profile of d-ampheta-
mine and not of intact LDX.
The present study also showed that LDX had a marked
and sustained effect on attention, behavior, and math
scores, as assessed by the SKAMP and PERMP scales. The
therapeutic effects associated with LDX were particularly
noticeable with regard to symptoms of inattention,
whereby LDX produced sustained efficacy compared with
placebo across all time points measured using the
SKAMP-A subscale. This study showed significant efficacy
and separation from placebo at the first time point of 1.5
hours postdose for the SKAMP-D, SKAMP-A, SKAMP
total, and PERMP scales, and at the 2.5-hour time point
for SKAMP quality of work subscale. LDX-treated subjects
in this study continued to show significant improvement
in all SKAMP- and PERMP-measured scales when com-
pared to treatment with placebo at all time points up to
and including 13 hours postdose (the last time point
assessed).
This study expanded and further refined findings from a
previous laboratory school study, due to a larger sample
size (129 vs 52), and additional time points assessed pre-
dose and 13-hour measurements (-0.5 to 13 hours in this
study vs 1 to 12 hours) [13]. In the previous study, treat-
ment effects were observed beginning at 2 hours postdose
and continued until 12 hours postdose. In addition,
results for CGI-I were similar in these 2 studies, which had
similar design and assessment schedules. In the previous
study, 74% of LDX-treated subjects were rated as
improved (ie, very much or much improved) [13] com-
pared with 82% of subjects in this study who were rated
as improved while on LDX during the crossover phase.
Consistent with the previous study, LDX was generally
well tolerated with most AEs reported as mild to moderate
in severity [13]. The AEs reported here were similar in
nature to those reported in studies of other stimulants and
included decreased appetite, insomnia, headache, irrita-
bility, upper abdominal pain, and affect lability
[10,13,27-29]. The frequency of newly reported AEs was
higher in the noncontrolled phase of this study than is
typically observed in stimulant clinical trials for decreased
appetite and insomnia. It is unclear why this increased
incidence occurred during the open-label phase of this
study. It is also unknown if it may be related to the prod-
rug release profile. However, it should be noted that dur-
ing the subsequent crossover phase, reported incidence of
AEs was generally comparable between LDX and placebo
treatments. The rate of discontinuations related to TEAEs
was consistent with those seen for other stimulants in
similar settings [10,30,31].
Predose time points had high (worsened) SKAMP deport-
ment and attention scores in the early morning hours in
both groups. However, higher (worse) ratings were evi-
dent in the LDX group compared with the placebo group
prior to dosing. While there may be multiple factors that
contributed to the higher ratings, the group differences
may be, in part, related to residual drug from the previous
treatment day as has been seen in another study with an
amphetamine-based long-acting stimulant [32]. Recent
studies of long-acting stimulants examining multiple
daily dose PK parameters suggest that residual plasma
drug levels from the previous day's dose are measurable
before dosing [24,33].
It is of interest that the onset of LDX efficacy for the
SKAMP quality of work scale was an hour later than that
seen for the other SKAMP subscales of attention and
deportment. This subscale of the SKAMP provides ratings
of completeness, correctness, and neatness of assigned
work versus other components of attention and interac-
tions with peers and adults during the observation peri-
ods. It is possible that the items of this subscale, which are
often grouped as a component of SKAMP-A, required a
longer interval to separate from placebo.
Modest increases in mean SBP, DBP, and pulse were
observed, consistent with the known effects of psychos-
timulants: typically increases of 2 to 4 mm Hg in blood
pressure and 3 to 6 bpm in heart rate are reported [21-23].
As noted earlier, the mean increase in pulse at 12.5 hours
postdose for the subjects receiving 70 mg LDX was higher
than typically seen. Interestingly, the mean increase in
pulse seen at 8.0 hours was lower in this group and in line
with pulse changes seen in the placebo group. The presentChild and Adolescent Psychiatry and Mental Health 2009, 3:17 http://www.capmh.com/content/3/1/17
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study does not include assessment of PK parameters and,
thus, such pharmacologic effects cannot be correlated
with relevant blood levels. While 14 subjects had one or
more abnormal QT/QTc intervals or abnormal QT/QTc
change from baseline, none had an interval ≥ 480 msec,
and no clinically meaningful trends were observed in ECG
parameters.
Strengths of the study included the use of a controlled lab-
oratory school setting, ratings by trained investigators,
and dose optimization, which mimicked dose titration in
clinical practice. The blinded design of the crossover
phase allowed a more valid assessment of patients at their
optimized dosage of LDX versus placebo. Reliability and
validity of SKAMP and PERMP scales were other strengths
as well as their inclusion as subjective and objective eval-
uations of efficacy, respectively.
Results should be viewed in light of study design limita-
tions. Consistent with laboratory school study designs,
the short treatment duration and assessment phases may
provide an underestimate of the number and severity of
TEAEs typically seen with lengthier treatment of ADHD.
Typical of ADHD studies, subjects with severe comorbid
psychiatric conditions were excluded. This may have
selected for a study population that under-represents psy-
chiatric comorbidities generally seen in ADHD popula-
tions [34]. Where efficacy assessments made during the
dose-optimization phase (ADHD-RS-IV and CGI-I) are
reported, it should be kept in mind that this was an open-
label phase of the study with limitations to interpretation
inherent to the unblinded design. While efficacy of LDX
compared with placebo was demonstrated up to and
including the last time point assessed (13 hours post-
dose), no measurements beyond 13 hours postdose were
captured. Further analysis and future studies will be
needed to determine the efficacy of LDX in relieving
ADHD symptoms at later time points. Other limitations
that may affect the ability to generalize these findings
include the uniformly high level of baseline severity of the
study subjects, the lack of a group of subjects with inatten-
tive type ADHD, and the under-representation of minor-
ity populations.
Conclusion
In a laboratory school setting, school-aged children with
ADHD taking LDX demonstrated significant improve-
ments relative to placebo in ADHD symptoms as meas-
ured by the SKAMP (attention and behavior), CGI
(improvement of illness), ADHD-RS-IV (hyperactivity/
impulsivity and inattention symptoms) (clinician-based),
and PERMP (academic productivity). Significant efficacy
compared with placebo was observed at each postdose
time point, at 1.5 hours, and up to and including 13.0
hours in this study as assessed during the crossover treat-
ment period. This time course is expected based on the PK
profile of the known, key therapeutic ingredient, d-
amphetamine. These findings suggest that LDX may pro-
vide effective symptom control in children with ADHD
throughout the day and that continues to afterschool
activities and family time.
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